Volume : 09, Issue : 10, October – 2022



Authors :

Jebitha J R *, Varsha V R, Kaveri B T, Subhash Chandran M P, Prasobh G R, Ms. Sariga Mohan

Abstract :

The 3D PRINTING technology has caught the attention of medical devices industry and pharmaceutical industry due to its applications on various platform in health care industry. Even though this technology exists for a long time it is of public interest highly now due to the approval of 3-D printed tablet and other medical devices and also with the advent of USFDA’s guidance on technical considerations specific to devices using additive manufacturing which encompasses 3-dimensional (3D) printing has triggered many thoughts about this technology which needs to be considered for successful delivery of intended product. The introduction of 3D printing technology in the pharmaceutical industry has opened new horizons in the research and development of printed materials and devices. The main benefits of 3D printing technology lie in the production of small batches of medicines, each with tailored dosages, shapes, sizes, and release characteristics. The manufacture of medicines in this way may finally lead to the concept of personalized medicines becoming a reality. This chapter provides an overview of how 3D printed technology has extended from initial unit operations to developed final products.

Cite This Article:

Please cite this article in Jebitha J R et al, 3 D Printing Technology In Pharmaceuticals: A Review., Indo Am. J. P. Sci, 2022; 09(10).

Number of Downloads : 10


1. Norman J, Madurawe R, Moore C, Khan MA, Khairuzzaman A. A new chapter in pharmaceutical manufacturing: 3D-printed drug products. Advanced Drug Delivery Reviews. 2017; 108:39-50
2. Diogo JH. 3D Printing of Pharmaceutical Drug Delivery Systems. Archives of Organic and Inorganic Chemical Sciences. 2018; 1(2). AOICS.MS.ID.000109.
3. Andrea AK, Marta GP, Dolores RS. Personalised 3D Printed Medicines: Which Techniques and Polymers Are More Successful?. Bioengineering. 2017; 4(79) , 1-16
4. Alhnan MA, Okwuosa TC, Muzna S, WaiWan K, Ahmed W, Arafat B. Emergence of 3D Printed Dosage Forms: Opportunities and Challenges. Pharmaceutical Research. 2016);33:1817–32 5.https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/3DPrintingofMedicalDevices/default.htm
6. http://cbm.msoe.edu/markMyweb/printResources/documents/historyOf3DPrinting.pdf
7. Wang, J, Goyanes A, Gaisford S, Basit AW. Stereolithographic (SLA) 3D printing of oral modified-release dosage forms. International Journal of Pharmaceutics. 2016; 503, 207–212.
8. Prasad LK, Smyth H. 3D printing technologies for drug delivery: A review. Drug Development and Industrial Pharmacy. 2016, 42, 1019–31.
9. Food and Drug Administration, 2017. Guidance for Industry: Technical Considerations for Additive Manufactured Medical Devices. Center for Devices and Radiological Health Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services. Available online:https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM499809.pdf
10. Food and Drug Administration, 2002, General Principles of Software Validation; Final Guidance for Industry and FDA Staff, Center for Devices and Radiological Health, Center for Biologics Evaluation and Research, U.S. Department Of Health and Human Services. https://www.fda.gov/downloads/medicaldevices/…/ucm085371.pdf
11. Prasad LK, Smyth H (2016) 3D Printing technologies for drug delivery: a review. Drug development and industrial pharmacy 42(7):1019–1031. https://doi.org/10.3109/03639045.2015.1120743
12. Daly R, Harrington TS, Martin GD (2015) Inkjet printing for pharmaceutics – a review of research and manufacturing. Int J Pharm 494(2):554 567.https://doi.org/10.1016/j.ijpharm.2015.03.017
13. Ursan ID, Chiu L (2003) Pierce A (2013) Three-dimensional drug printing: a structured review. J Am Pharm Assoc 53(2):136–144. https://doi.org/10.1331/ JAPhA.2013.12217
14. Jamroz W, Szafraniec J, Kurek M (2018) 3D printing in pharmaceutical and medical applications – recent achievements and challenges. Pharm Res 35(9):176. https://doi.org/10.1007/s11095-018-2454-x
15. Palo M, Hollander J, Suominen J (2017) 3D printed drug delivery devices: perspectives and technical challenges. Expert Rev Med Devices 14(9):685– 696. https://doi.org/10.1080/17434440.2017.1363647
16. Park K (2015) 3D printing of 5-drug polypill. J Control Release 217:352. https://doi.org/10.1016/j.jconrel.2015.10.014
17. Sun Y, Soh S (2015) Printing tablets with fully customizable release profiles for personalized medicine. Advanced materials (Deerfield Beach, Fla.) 27(47):7847-7853. https://doi.org/10.1002/adma.201504122
18. Trenfield SJ, Awad A, Goyanes A (2018) 3D Printing pharmaceuticals: drug development to frontline care. Trends Pharmacol Sci 39:440–451. https:// doi.org/10.1016/j.tips.2018.02.006
19. Goole J, Amighi K (2016) 3D printing in pharmaceutics: a new tool for designing customized drug delivery systems. Int J Pharm 499(1):376–394. https://doi.org/10.1016/j.ijpharm.2015.12.071
20. Osouli-Bostanabad K, Adibkia K (2018) Made-on-demand, complex and personalized 3D-printed drug products. BioImpacts : BI 8 (2):77-79. doi:10.15171/bi.2018.09
21. Khatri P, Shah MK, Vora N (2018) Formulation strategies for solid oral dosage form using 3D printing technology: a mini-review. J DRUG DELIV SCI TEC46:148–155. https://doi.org/10.1016/j.jddst.2018.05.009
22. Deciding When to Submit a 510(k) for a Change to an Existing Device. Available online: www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm080235.htm)
23. 30-Day Notices, 135-Day Premarket Approval (PMA) Supplements and 75-Day Humanitarian Device Exemption (HDE) Supplements for Manufacturing Method or Process Changes. Available online: www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM080194.pdf
24. Modifications to Devices Subject to Premarket Approval (PMA) – The PMA Supplement Decision-MakingProcess. https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm089360.pdf
25. Changes or Modifications During the Conduct of a Clinical Investigation. Available online: www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm082158.pdf
26. Outterson K. Regulating compounding pharmacies after NECC. The New England Journal of Medicine. 2012; 367(21):1969–72.
27. Drues M. The case of the New England Compounding Center. Healthcare packaging. 8/11/15. Available from: http://www.healthcarepackaging.com/case-new-england-compoundingcenter.
28. Sun L. FDA finds widespread safety issues at compounding pharmacies. In.Washington Post: Health & Science. 2013.
29. Katakam P, Dey B, Assaleh FH, Hwisa NT, Adiki SK, Chandu BR, et al. Top-down and bottom-up approaches in 3D printing technologies for drug delivery challenges. Critical Reviews in Therapeutic Drug Carrier Systems. 2015;32(1):61-87
30. Goyanes A, Buanz AB, Hatton GB, Gaisford S, Basit AW. 3D printing
of modified-release aminosalicylate (4-ASA and 5-ASA) tablets. European Journal of Pharmaceutics and Biopharmaceutics. 2015;89:157-162
31. Masood SH. Application of fused deposition modelling in controlled drug delivery devices. Assembly Automation. 2007 Aug 7;27(3):215-221
32. Buanz AB, Saunders MH, Basit AW, Gaisford S. Preparation of personalized-dose salbutamol sulphate oral films with thermal ink-jet printing. Pharmaceutical Research. 2011;28(10):2386
33. Meléndez PA, Kane KM, Ashvar CS, Albrecht M, Smith PA. Thermal inkjet application in the preparation of oral dosage forms: Dispensing of prednisolone solutions and polymorphic characterization by solid-state spectroscopic techniques. Journal of Pharmaceutical Sciences. 2008;97(7):2619-2636